BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Diagnosis
12 results:

  • 1. Clinico-genomic Characterization of ATM and HRD in Pancreas cancer: Application for Practice.
    Park W; O'Connor CA; Bandlamudi C; Forman D; Chou JF; Umeda S; Reyngold M; Varghese AM; Keane F; Balogun F; Yu KH; Kelsen DP; Crane C; Capanu M; Iacobuzio-Donahue C; O'Reilly EM
    Clin Cancer Res; 2022 Nov; 28(21):4782-4792. PubMed ID: 36040493
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF-β pathway via miR-148a-3p/AGO1 axis.
    Wu Y; Gu W; Han X; Jin Z
    J Cell Mol Med; 2021 Sep; 25(17):8229-8243. PubMed ID: 34288373
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer.
    Song J; Le T; Hopkins L; Fung-Kee-Fung M; Lupe K; Gaudet M; E C; Samant R
    Int J Gynecol Cancer; 2020 Feb; 30(2):160-166. PubMed ID: 31871112
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/smad4 signaling pathway.
    Zhou J; Zhang C; Zhou B; Jiang D
    Int J Mol Med; 2019 Apr; 43(4):1734-1746. PubMed ID: 30720057
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
    Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
    Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
    Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Metastatic mucinous carcinomas in the ovary: a practical approach to diagnosis related to gross aspects and to immunohistochemical evaluation.
    Pinto PB; Derchain SF; Andrade LA
    Int J Gynecol Pathol; 2012 Jul; 31(4):313-8. PubMed ID: 22653343
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Hereditary colorectal cancer].
    Park JG; Kim IJ
    Korean J Gastroenterol; 2005 Feb; 45(2):78-87. PubMed ID: 15725711
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
    Cao D; Ji H; Ronnett BM
    Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
    Baker PM; Oliva E
    Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Problems in histological diagnosis of intraductal papillary-mucinous tumor (IPMT).
    Nagasaka T; Nakashima N
    Hepatogastroenterology; 2001; 48(40):972-6. PubMed ID: 11490851
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations.
    Wirtzfeld DA; Petrelli NJ; Rodriguez-Bigas MA
    Ann Surg Oncol; 2001 May; 8(4):319-27. PubMed ID: 11352305
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.